Teva  Pharmaceutical: stock slided to its lowest in 17 years a day after chief executive Kare Schultz took the helm. Photographer: Chris Ratcliffe/Bloomberg

Teva Pharmaceutical’s outlook worsened after the world’s biggest maker of copycat drugs cut its annual profit target for a third time, prompting the s(...)

Boxes of tablets produced by Teva. The Israeli generics giant  has prised Kaare Schultz from  Lundbeck with a $40m   package. Photograph: Chris Ratcliffe/Bloomberg

Teva Pharmaceutical is betting $40 million (€44.4m) that the man credited with the rapid revival of a Danish drugmaker can do it again – and it’s brea(...)

Workers at  AstraZeneca’s  Macclesfield site in England.  Shares in the British drug giant suffered their largest ever fall as it announced a big setback, with a much-awaited trial of a new lung cancer drug failing to show the benefits for which the company had hoped. Photograph: Phil Noble/Reuters

Shares in AstraZeneca were on track to suffer their worst ever fall after the Anglo-Swedish pharmaceutical company suffered a big setback with a much-(...)

Teva said it expected to integrate the generics business quickly, and is planning to launch 1,500 generics globally next year. Photograph: iStock

Teva Pharmaceutical said it has completed the acquisition of Allergan’s generics business, Actavis Generics. The deal was announced in July last yea(...)

Allergan, which is run from New Jersey but has a legal domicile in Dublin, last year agreed to merge with Pfizer in a $160 billion deal that would give New York-based Pfizer a foreign address and a lower tax rate. (Photograph: ANDREW GOMBERT/EPA)

Allergan Plc shares plummeted 21 per cent in late trading Monday after the US Treasury Department released rules that would limit the ability of US c(...)

Mylan, which first made a bid for Perrigo in April, went hostile in September, offering $75 in cash and 2.3 of its shares for each Perrigo share

Generic drug maker Mylan said on Friday that 40 per cent of Perrigo ’s shares were tendered in its $26 billion hostile takeover offer, falling short o(...)

Teva Pharmaceutical has built a 4.6 per cent share of Mylan over the past months. Photographer: Akos Stiller/Bloomberg

Teva Pharmaceutical, the Israeli drugmaker, is nearing a deal to acquire Allergan’s generics drug unit for between $40 billion and $45 billion, accord(...)

Robert J. Coury, vice-chairman and chief executive of Mylan. Photographer: Mannie Garcia/Bloomberg News

Generic drugs group Mylan boosted its cash-and-stock offer to buy Irish company Perrigo to $34.10 billion, but the bid was swiftly rejected.Mylan’s p(...)